Pasar al contenido principal

DEFINIR LOS PROCESOS CELLULARES A TRAVES DE LOS CUALES EL P53 SUPRIME LOS TUMORES

PID2021-127710OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

  • Martínez Bosch, Neus
  • Manero Rupérez, Noemí
  • Vázquez-Bellón, Núria
  • Nickell-Hernández, Bennett
  • Ventura-Blanch, Cristina
  • Lutfi, Nura
  • Lechuga, Carmen G.
  • Martínez, Carlos
  • Moreno, Mireia
  • Ampurdanés, Coral
  • Abad Cortel, Etna
  • Iglesias Coma, Mar
  • Muñoz-Escribano, María
  • Janic, Ana
  • Rovira, Meritxell
  • Guerra, Carmen
  • Rabinovich, Gabriel A.
  • Yélamos López, José
  • Navarro, Pilar
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

  • Abad Cortel, Etna
  • Sandoz, Jérémy
  • Romero, Gerard
  • Zadra, Ivan
  • Urgel i Solas, Júlia
  • Borredat Díaz, Pablo
  • Kourtis, Savvas
  • Ortet Cortada, Laura
  • Martínez, Carlos
  • Weghorn, Donate
  • Sdelci, Sara
  • Janic, Ana
Background: TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, we investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers. Methods: Employing TP53 wild-type cells, we generated models lacking RNF144B in both non-transformed and cancerous cells of human and mouse origin. By using proteomics, transcriptomics, and functional analysis, we assessed RNF144B's impact in cellular proliferation and transformation. Through in vitro and in vivo experiments, we explored proliferation, DNA repair, cell cycle control, mitotic progression, and treatment resistance. Findings were contrasted with clinical datasets and bioinformatics analysis. Results: Our research underscores RNF144B's pivotal role as a tumor suppressor, particularly in lung adenocarcinoma. In both human and mouse oncogene-expressing cells, RNF144B deficiency heightened cellular proliferation and transformation. Proteomic and transcriptomic analysis revealed RNF144B's novel function in mediating protein degradation associated with cell cycle progression, DNA damage response and genomic stability. RNF144B deficiency induced chromosomal instability, mitotic defects, and correlated with elevated aneuploidy and worse prognosis in human tumors. Furthermore, RNF144B-deficient lung adenocarcinoma cells exhibited resistance to cell cycle inhibitors that induce chromosomal instability. Conclusions: Supported by clinical data, our study suggests that RNF144B plays a pivotal role in maintaining genomic stability during tumor suppression., This work was supported by grants and fellowships from the Spanish Ministry of Science and Development Grant to A.J. (PID2021-127710OB-I00) and “La Caixa” foundation (51110009). A.J. is supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I). I.Z. is funded by an AECC Postdoctoral Fellowship (POSTD234858ZADR), and J.U. by La Caixa PhD Scholarship (LCF/BQ/DR22/11950019). This work was made possible through the “Unidad de Excelencia María de Maeztu'' funded by the MCIN and AEI (CEX2018-000792-M).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research

  • Zadra, Ivan
  • Abad Cortel, Etna
  • Krasko, Anastasia
  • Cerdán Porqueras, Víctor
  • Subirana-Granés, Marc
  • Reyes, Diana
  • Borredat Díaz, Pablo
  • Pasquali, Lorenzo
  • Aramburu, José (Aramburu Beltrán)
  • López Rodríguez, M. Cristina
  • Janic, Ana
Immunotherapy has revolutionised cancer treatment, yet responses vary significantly based on tumour characteristics and microenvironment. Here, we developed and analysed subcutaneous and orthotopic immunocompetent mice models of mismatch repair-deficient (dMMR) lung adenocarcinoma (LUAD) by selectively ablating Mlh1. Subcutaneous tumours demonstrated partial sensitivity to anti-PD-1 therapy, whereas orthotopic tumours exhibited robust responses, with substantial reductions in tumour burden. Although both models displayed to some extent a robust immune microenvironment, they differed in immune cell infiltration patterns following anti-PD-1 treatment, underscoring the critical influence of anatomical site and tumour context in shaping immunotherapy outcomes. Furthermore, the use of clonal cell lines with enriched neoantigen frequency in the orthotopic model highlighted the role of clonal heterogeneity in modulating therapeutic efficacy. Together, our findings emphasise the relevance of orthotopic models for preclinical evaluation and suggest that they more accurately reflect clinical responses to immune checkpoint blockade in dMMR LUAD., We thank Dr A. Celià-Terrassa, and Dr. K. Sutherland for providing reagents; Dr. Yacine Kharraz and CRG/UPF Flow Cytometry Unit with sample preparation and analysis. This work was supported by grants from the Spanish Ministry of Science and Innovation Grant (PID2021-127710OB-I00, PID2021-128721OB-I00, PID2023-151556OB-I00, CNS2024-154742, CNS2023-144819), “La Caixa” foundation (51110009 and HR22-00402), Worldwide Cancer Research (20–0144), ESF+ (ERDF A way of making Europe), European Union NextGenerationEU/PRTR (ESF Investing in your future). A.J. was supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I), I.Z. is funded by an AECC Postdoctoral Fellowship (POSTD234858ZADR). C.L.-R. is supported by the ICREA Acadèmia program of Generalitat de Catalunya. A.K. was supported by a predoctoral fellowship of the Spanish Ministry of Science and Innovation (PRE2019-088166). L.P. was founded by PID2023-151556OB-I00, CNS2024-154742, “ERDF A way of making Europe” and, as appropriate, by “ESF Investing in your future”, by “ESF+” or by “European Union NextGenerationEU/PRTR”. This work was made possible through the “Unidad de Excelencia María de Maeztu'' funded by the MCIN and AEI (CEX2018-000792-M).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice

  • Brennan, Margs S.
  • Brinkmann, Kerstin
  • Romero Sola, Gerard
  • Healey, Geraldine
  • Gibson, Leonie
  • Gangoda, Lahiru
  • Potts, Margaret A.
  • Lieschke, Elizabeth C.
  • Wilcox, Stephen
  • Strasser, Andreas
  • Herold, Marco J.
  • Janic, Ana
Transcriptional activation of target genes is essential for TP53-mediated tumour suppression, though the roles of the diverse TP53-activated target genes in tumour suppression remains poorly understood. Knockdown of ZMAT3, an RNA-binding zinc-finger protein involved in regulating alternative splicing, in haematopoietic cells by shRNA caused leukaemia only with the concomitant absence of the PUMA and p21, the critical effectors of TRP53-mediated apoptosis and cell cycle arrest respectively. We were interested to further investigate the role of ZMAT3 in tumour suppression beyond the haematopoietic system. Therefore, we generated Zmat3 knockout and compound gene knockout mice, lacking Zmat3 and p21, Zmat3 and Puma or all three genes. Puma-/-p21-/-Zmat3-/- triple knockout mice developed tumours at a significantly higher frequency compared to wild-type, Puma-/-Zmat3-/- or p21-/-Zmat3-/-deficient mice. Interestingly, we observed that the triple knockout and Puma-/-Zmat3-/- double deficient animals succumbed to lymphoma, while p21-/-Zmat3-/- animals developed mainly solid cancers. This analysis suggests that in addition to ZMAT3 loss, additional TRP53-regulated processes must be disabled simultaneously for TRP53-mediated tumour suppression to fail. Our findings reveal that the absence of different TRP53 regulated tumour suppressive processes changes the tumour spectrum, indicating that different TRP53 tumour suppressive pathways are more critical in different tissues., This work was supported by grants and fellowships from the Australian Phenomics Network (APN), the Australian National Health and Medical Research Council (NHMRC) to MJH and AS (1143105), Programme Grant to AS (1016701), Investigator grant to AS (2007887), Investigator Grant to MJH (2017971); the Leukaemia and Lymphoma Society of America to AS and MJH (LLS SCOR 7015-18); the Cancer Council of Victoria Project grant to AS (1052309) and Venture Grant to MJH and AS; support to AS from the estate of Anthony (Toni) Redstone OAM; support to AJ from Spanish Ministry of Economy and Development Grant (PID2021-127710OB-I00) and Programa Captació de Talent Investigador ‘La Caixa’ foundation (51110009). AJ is supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I), AS and MJH are supported by NHMRC Fellowships (1020363 and 1156095), MSB is supported by Cancer Council Victoria Postdoctoral Fellowship and Swedish Cancer Society (21 0355 PT). This work was made possible through the Victorian Government Operational Infrastructure Support and Australian Government, the ‘Unidad de Excelencia María de Maeztu’ funded by the Spanish Government.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice

  • Brennan, Margs S.
  • Brinkmann, Kerstin
  • Romero Sola, Gerard
  • Healey, Geraldine
  • Gibson, Leonie
  • Gangoda, Lahiru
  • Potts, Margaret A.
  • Lieschke, Elizabeth C.
  • Wilcox, Stephen
  • Strasser, Andreas
  • Herold, Marco J.
  • Janic, Ana
Transcriptional activation of target genes is essential for TP53-mediated tumour suppression, though the roles of the diverse TP53-activated target genes in tumour suppression remains poorly understood. Knockdown of ZMAT3, an RNA-binding zinc-finger protein involved in regulating alternative splicing, in haematopoietic cells by shRNA caused leukaemia only with the concomitant absence of the PUMA and p21, the critical effectors of TRP53-mediated apoptosis and cell cycle arrest respectively. We were interested to further investigate the role of ZMAT3 in tumour suppression beyond the haematopoietic system. Therefore, we generated Zmat3 knockout and compound gene knockout mice, lacking Zmat3 and p21, Zmat3 and Puma or all three genes. Puma-/-p21-/-Zmat3-/- triple knockout mice developed tumours at a significantly higher frequency compared to wild-type, Puma-/-Zmat3-/- or p21-/-Zmat3-/-deficient mice. Interestingly, we observed that the triple knockout and Puma-/-Zmat3-/- double deficient animals succumbed to lymphoma, while p21-/-Zmat3-/- animals developed mainly solid cancers. This analysis suggests that in addition to ZMAT3 loss, additional TRP53-regulated processes must be disabled simultaneously for TRP53-mediated tumour suppression to fail. Our findings reveal that the absence of different TRP53 regulated tumour suppressive processes changes the tumour spectrum, indicating that different TRP53 tumour suppressive pathways are more critical in different tissues., This work was supported by grants and fellowships from the Australian Phenomics Network (APN), the Australian National Health and Medical Research Council (NHMRC) to MJH and AS (1143105), Programme Grant to AS (1016701), Investigator grant to AS (2007887), Investigator Grant to MJH (2017971); the Leukaemia and Lymphoma Society of America to AS and MJH (LLS SCOR 7015-18); the Cancer Council of Victoria Project grant to AS (1052309) and Venture Grant to MJH and AS; support to AS from the estate of Anthony (Toni) Redstone OAM; support to AJ from Spanish Ministry of Economy and Development Grant (PID2021-127710OB-I00) and Programa Captació de Talent Investigador ‘La Caixa’ foundation (51110009). AJ is supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I), AS and MJH are supported by NHMRC Fellowships (1020363 and 1156095), MSB is supported by Cancer Council Victoria Postdoctoral Fellowship and Swedish Cancer Society (21 0355 PT). This work was made possible through the Victorian Government Operational Infrastructure Support and Australian Government, the ‘Unidad de Excelencia María de Maeztu’ funded by the Spanish Government.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research

  • Zadra, Ivan
  • Abad Cortel, Etna
  • Krasko, Anastasia
  • Cerdán Porqueras, Víctor
  • Subirana-Granés, Marc
  • Reyes, Diana
  • Borredat Díaz, Pablo
  • Pasquali, Lorenzo
  • Aramburu, José (Aramburu Beltrán)
  • López Rodríguez, M. Cristina
  • Janic, Ana
Immunotherapy has revolutionised cancer treatment, yet responses vary significantly based on tumour characteristics and microenvironment. Here, we developed and analysed subcutaneous and orthotopic immunocompetent mice models of mismatch repair-deficient (dMMR) lung adenocarcinoma (LUAD) by selectively ablating Mlh1. Subcutaneous tumours demonstrated partial sensitivity to anti-PD-1 therapy, whereas orthotopic tumours exhibited robust responses, with substantial reductions in tumour burden. Although both models displayed to some extent a robust immune microenvironment, they differed in immune cell infiltration patterns following anti-PD-1 treatment, underscoring the critical influence of anatomical site and tumour context in shaping immunotherapy outcomes. Furthermore, the use of clonal cell lines with enriched neoantigen frequency in the orthotopic model highlighted the role of clonal heterogeneity in modulating therapeutic efficacy. Together, our findings emphasise the relevance of orthotopic models for preclinical evaluation and suggest that they more accurately reflect clinical responses to immune checkpoint blockade in dMMR LUAD., We thank Dr A. Celià-Terrassa, and Dr. K. Sutherland for providing reagents; Dr. Yacine Kharraz and CRG/UPF Flow Cytometry Unit with sample preparation and analysis. This work was supported by grants from the Spanish Ministry of Science and Innovation Grant (PID2021-127710OB-I00, PID2021-128721OB-I00, PID2023-151556OB-I00, CNS2024-154742, CNS2023-144819), “La Caixa” foundation (51110009 and HR22-00402), Worldwide Cancer Research (20–0144), ESF+ (ERDF A way of making Europe), European Union NextGenerationEU/PRTR (ESF Investing in your future). A.J. was supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I), I.Z. is funded by an AECC Postdoctoral Fellowship (POSTD234858ZADR). C.L.-R. is supported by the ICREA Acadèmia program of Generalitat de Catalunya. A.K. was supported by a predoctoral fellowship of the Spanish Ministry of Science and Innovation (PRE2019-088166). L.P. was founded by PID2023-151556OB-I00, CNS2024-154742, “ERDF A way of making Europe” and, as appropriate, by “ESF Investing in your future”, by “ESF+” or by “European Union NextGenerationEU/PRTR”. This work was made possible through the “Unidad de Excelencia María de Maeztu'' funded by the MCIN and AEI (CEX2018-000792-M).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

  • Martínez Bosch, Neus
  • Manero Rupérez, Noemí
  • Vázquez-Bellón, Núria
  • Nickell-Hernández, Bennett
  • Ventura-Blanch, Cristina
  • Lutfi, Nura
  • Lechuga, Carmen G.
  • Martínez, Carlos
  • Moreno, Mireia
  • Ampurdanés, Coral
  • Abad Cortel, Etna
  • Iglesias Coma, Mar
  • Muñoz-Escribano, María
  • Janic, Ana
  • Rovira, Meritxell
  • Guerra, Carmen
  • Rabinovich, Gabriel A.
  • Yélamos López, José
  • Navarro, Pilar
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

  • Abad Cortel, Etna
  • Sandoz, Jérémy
  • Romero, Gerard
  • Zadra, Ivan
  • Urgel i Solas, Júlia
  • Borredat Díaz, Pablo
  • Kourtis, Savvas
  • Ortet Cortada, Laura
  • Martínez, Carlos
  • Weghorn, Donate
  • Sdelci, Sara
  • Janic, Ana
Background: TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, we investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers. Methods: Employing TP53 wild-type cells, we generated models lacking RNF144B in both non-transformed and cancerous cells of human and mouse origin. By using proteomics, transcriptomics, and functional analysis, we assessed RNF144B's impact in cellular proliferation and transformation. Through in vitro and in vivo experiments, we explored proliferation, DNA repair, cell cycle control, mitotic progression, and treatment resistance. Findings were contrasted with clinical datasets and bioinformatics analysis. Results: Our research underscores RNF144B's pivotal role as a tumor suppressor, particularly in lung adenocarcinoma. In both human and mouse oncogene-expressing cells, RNF144B deficiency heightened cellular proliferation and transformation. Proteomic and transcriptomic analysis revealed RNF144B's novel function in mediating protein degradation associated with cell cycle progression, DNA damage response and genomic stability. RNF144B deficiency induced chromosomal instability, mitotic defects, and correlated with elevated aneuploidy and worse prognosis in human tumors. Furthermore, RNF144B-deficient lung adenocarcinoma cells exhibited resistance to cell cycle inhibitors that induce chromosomal instability. Conclusions: Supported by clinical data, our study suggests that RNF144B plays a pivotal role in maintaining genomic stability during tumor suppression., This work was supported by grants and fellowships from the Spanish Ministry of Science and Development Grant to A.J. (PID2021-127710OB-I00) and “La Caixa” foundation (51110009). A.J. is supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I). I.Z. is funded by an AECC Postdoctoral Fellowship (POSTD234858ZADR), and J.U. by La Caixa PhD Scholarship (LCF/BQ/DR22/11950019). This work was made possible through the “Unidad de Excelencia María de Maeztu'' funded by the MCIN and AEI (CEX2018-000792-M).